Mount Sinai Health System · 1 week ago
Postdoctoral Fellow-MSH-13050-221
Maximize your interview chances
Health CareHospital
Actively Hiring
Insider Connection @Mount Sinai Health System
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Autophagy-lysosome dysfunctions in neurons and glial cells in the pathogenesis of neurodegenerative diseases
We propose to elucidate the cell-type-specific autophagy-lysosome pathways, focusing on neurons and microglia, under both physiological (young and old) and pathological conditions (Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease). Employing a systematic approach, we will incorporate multiple genetic mutant lines of mice, human-induced neuron lines (hiN), quantitative proteomics, and molecular and cell biology techniques to identify autophagy cargo and receptors in neurons and microglia. Furthermore, we will investigate the distinct mechanisms responsible for the degradation of multiple disease-associated proteins such as tau, alpha-synuclein (aSyn), and huntingtin. The findings of our study hold the potential to uncover novel biomarkers and therapeutic targets for autophagy-lysosomes in the treatment of Alzheimer’s, Parkinson’s, and Huntington’s diseases, thereby paving the way for innovative therapeutic interventions.
Dysfunctional AKAP11-PKA signaling underlying the pathogenic mechanism and in modeling psychiatric disease condition (schizophrenia and bipolar)
Recent human genetic study has identified AKAP11 as a definitive causal gene for bipolar disorder and enhanced risk factor for schizophrenia. Our study demonstrated AKAP11 is an autophagy receptor that mediates selective degradation of PKA-RI complex through autophagy. Our goal is to dissect the pathogenic mechanism whereby AKAP11 deficiency contributes to the psychiatric illness by characterizing genetic animal models and induced human neuron (iNeuron) models. We will test the new therapeutic ideas by targeting AKAP11-PKA signaling and activity.
Flow-cytometry
ELISA
WB
ELISPOT
QPCR
CyTOF data analyses
Mouse genetics
Molecular and cellular biology approaches
Primary neuron/glia cultures
Cellular imaging (both live and fixed)
Transcriptomics (including single-cell RNA sequencing and spatial transcriptomics)
Proteomics
Bioinformatics
Animal pathology/behavioral studies
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
MD or PhD
Extensive training in basic neuroscience, molecular and cellular biology, animal models, and neurological disorder mechanism research.
Company
Mount Sinai Health System
Mount Sinai Health System delivers integrated medical care, research, and medical education through its network.
Funding
Current Stage
Late StageTotal Funding
$41.9MKey Investors
National Institutes of HealthHearst Health Prize.Multiple Myeloma Research Foundation
2024-11-11Grant· $7M
2024-06-06Grant· $0.1M
2023-11-02Grant· $7M
Leadership Team
Recent News
2024-12-17
GlobeNewswire News Room
2024-12-05
Company data provided by crunchbase